Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.

Journal of clinical pharmacology - 1 Feb 2014

Seng Kok-Yong, Hee Kim-Hor, Soon Gaik Hong, Sapari Nur Sabrina, Soong Richie, Goh Boon-Cher, Lee Lawrence Soon-U

Abstract excerpt

We aim to evaluate the influence of covariates, including cytochrome P450 3A (CYP3A) genetic polymorphisms, on the pharmacokinetics of midazolam (MDZ) in Asian cancer patients, using a population pharmacokinetic approach. Pharmacokinetic data were obtained from 24 adult cancer patients who received an intravenous bolus dose of 1 mg MDZ as a CYP3A phenotyping probe, 1-day before starting FOLFIRI chemotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Anxiety Agents
Share to Bilirubin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Body Weight

Share to Creatinine

Share to Cytochrome P-450 CYP3A

Share to Glucuronosyltransferase

Share to Injections, Intravenous

Share to Midazolam

Source

Identifiers

PMID: 24214410
DOI: 10.1002/jcph.230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.PMID 24214410Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.Semantic proximity Read ↗

Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients.Semantic proximity Read ↗

Contributing factors on metabolic mechanism-based CYP3A4-activated/deactivated anticancer drugs: implications for individualizing chemotherapySemantic proximity Read ↗

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.Semantic proximity Read ↗

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read ↗

Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.Semantic proximity Read ↗

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.Semantic proximity Read ↗

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.Semantic proximity Read ↗

Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.Semantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.